ReviewJournal of clinical medicine2024
Intersecting Pathways: The Role of Metabolic Dysregulation, Gastrointestinal Microbiome, and Inflammation in Acute Ischemic Stroke Pathogenesis and Outcomes.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Host-Microbiota Metabolic Interactions in Atherosclerosis: Oral, gut, and Blood Perspectives.Probiotics and antimicrobial proteins · 2026Review
- New Adjuvant Therapies for Obesity-Related Disorders Associated with Meta-Neuroinflammation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Predicting Stroke Incidence Using Estimated Glucose Disposal Rate Index in the Population with Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 in the Chinese Middle-Aged and Elderly Population.Cardiorenal medicine · 2026Observational
- Cumulative inflammatory, coagulation, and metabolic abnormalities predict poor 90-day functional outcome after endovascular thrombectomy for large-vessel occlusion acute ischemic stroke.Frontiers in neurology · 2026Article
- Identification of a novel metabolic and lipidomic signature for 90-day functional outcome after ischemic stroke: an exploratory proof-of-concept study.Frontiers in neurology · 2026Article
- Analysis of factors influencing short-term outcomes after early interventional therapy for acute ischaemic stroke.BMC neurology · 2025Article
- Tracing Inflammation in Ischemic Stroke: Biomarkers and Clinical Insight.International journal of molecular sciences · 2025Review
- A Comprehensive Review of the Role of the Microbiota-Gut-Brain Axis via Neuroinflammation: Advances and Therapeutic Implications for Ischemic Stroke.Biomolecules · 2025Review
- Zebrafish navigating the metabolic maze: insights into human disease - assets, challenges and future implications.Journal of diabetes and metabolic disorders · 2025Review
- Threshold of phenylacetylglutamine changes: exponential growth between age and gut microbiota in stroke patients.Frontiers in neurology · 2025Article
- Integration of gut microbiota, Stroke Dysbiosis Index, and inflammatory biomarkers in assessing prognosis of acute ischemic stroke.Frontiers in medicine · 2025Article
- Intestinal ischemia-reperfusion and blood-brain barrier compromise: pathways to cognitive dysfunction.Frontiers in neuroscience · 2025Review
- Potential Mechanism and Perspectives of Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Review.Global medical genetics · 2024Review
- Explainable machine learning reveals multifactorial drivers of early intracranial hematoma progression in traumatic brain injury: development of a SHAP-guided SVM nomogram.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke (AIS) remains a major cause of mortality and long-term disability worldwide, driven by complex and multifaceted etiological factors. Metabolic dysregulation, gastrointestinal microbiome alterations, and systemic inflammation are emerging as significant contributors to AIS pathogenesis. This review addresses the critical need to understand how these factors interact to influence AIS risk and outcomes. We aim to elucidate the roles of dysregulated adipokines in obesity, the impact of gut microbiota disruptions, and the neuroinflammatory cascade initiated by lipopolysaccharides (LPS) in AIS. Dysregulated adipokines in obesity exacerbate inflammatory responses, increasing AIS risk and severity. Disruptions in the gut microbiota and subsequent LPS-induced neuroinflammation further link systemic inflammation to AIS. Advances in neuroimaging and biomarker development have improved diagnostic precision. Here, we highlight the need for a multifaceted approach to AIS management, integrating metabolic, microbiota, and inflammatory insights. Potential therapeutic strategies targeting these pathways could significantly improve AIS prevention and treatment. Future research should focus on further elucidating these pathways and developing targeted interventions to mitigate the impacts of metabolic dysregulation, microbiome imbalances, and inflammation on AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.